Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

IMOVAX POLIO INJECTION [SIN10608P]

Active ingredients: INACTIVATED POLIOMYELITIS VIRUS TYPE 1 (MAHONEY) | INACTIVATED POLIOMYELITIS VIRUS TYPE 2 (MEF-1) | INACTIVATED POLIOMYELITIS VIRUS TYPE 3 (SAUKETT)

View product's general information
Last updated on 9 October 2026

Product Info

IMOVAX POLIO INJECTION

[SIN10608P]

Product information

Active Ingredient and Strength

INACTIVATED POLIOMYELITIS VIRUS TYPE 1 (MAHONEY) - 40 D.U./0.5 ML
INACTIVATED POLIOMYELITIS VIRUS TYPE 2 (MEF-1) - 8 D.U./0.5 ML
INACTIVATED POLIOMYELITIS VIRUS TYPE 3 (SAUKETT) - 32 D.U./0.5 ML

Dosage Form

INJECTION

Manufacturer and Country

SANOFI PASTEUR - FRANCE

Registration Number

SIN10608P

Licence Holder

SANOFI-AVENTIS SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J07BF03

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

Therapeutic indications

This vaccine is indicated for the prevention of poliomyelitis in infants, children and adults, for primary and booster vaccination.

IMOVAX POLIO (IPV) must be used according to effective official recommendations.

Dosing

Posology and method of administration

Posology

  • From the age of 2 months, 3 successive doses of 0.5 mL of IMOVAX POLIO should be administered at intervals of one or two months, followed by a first booster 12 months after the last dose.

  • For subsequent boosters, an injection is given every 5 years in children and adolescents and every 10 years in adults.

  • In countries where a live Oral Poliomyelitis vaccine (trivalent, bivalent or monovalent OPV) is used in the routine immunisation programme, IMOVAX POLIO may be used in association (co-administration) or in sequential use with OPV, in accordance with WHO recommendations and in agreement with the national recommendations in effect.

Method of administration

Administration is performed preferably via the intramuscular (IM) route, or via the subcutaneous (SC) route.

Intramuscular injection will be preferably performed in the antero-lateral side of the thigh in young children and in the deltoid muscle in children, adolescents and adults.

For instructions on use, handling and disposal, see section Special precautions for disposal and other handling – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Contraindications

Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information, or to any vaccine containing the same substances, to neomycin, streptomycin or polymyxin B.

Common transient contraindications to any vaccination: in case of fever or acute illness, it is best to postpone vaccination.